Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00236015 · ClinicalTrials.gov registry record · Phase 3
A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
A Phase 3 study of Anxiety Disorder, sponsored by Cephalon.
- Completed
- Registry status
- Phase 3
- Development phase
- 880
- Enrollment target
- 20
- Study locations
NCT00236015: Completed Phase 3 study of Anxiety Disorder, sponsored by Cephalon.
NCT00236015 is a Phase 3 study of Anxiety Disorder that has completed, run by Cephalon. The registered enrollment target is 880 participants, above the 381-participant average among 20 other Anxiety Disorder trials with a reported enrollment target (131% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00236015, a Phase 3 study of Anxiety Disorder, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 880 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).
Conditions Studied
Interventions
- DRUG Gabitril
Study Locations (20)
California
- Valley Clinical Research - El Centro
- Radiant Research Irvine - Irvine
- Pharmacology Research Institute - Los Alamitos
- Pharmacology Research Institute - Riverside
- Clinical Innovations, Inc. - Santa Ana
Florida
- Miami Research Associates - Miami
- Medical Research Group of Central Florida - Orange City
- Clinical Neuroscience Solutions, Inc. - Orlando
- Roskamp Institute, Clinical Trials Division - Sarasota
- Stedman Clinical Trials - Tampa
Illinois
- American Medical Research - Aurora
- Henry Lahmeyer MD & Associates - Northfield
- Midwest Center for Neurobehavioral Medicine - Oakbrook Terrace
Arizona
- Pivotol Research Centers - Mesa
- Pivotal Research Center - Peoria
Colorado
- Radiant Research - Denver
Connecticut
- University of Connecticut Health Center - Farmington
Georgia
- Emory University - Atlanta
Indiana
- Indiana University Hospital AOC - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 880 participants |
| Start Date | 2004-11 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
What the finished NCT00236015 record still lists
NCT00236015 is an interventional study that assigns participants to a tested intervention. The registered 880 participants enrollment target is mid-sized for trials with a published cap, above the 381-participant average among 20 other Anxiety Disorder trials with a reported enrollment target (131% higher).
The record links to 1 condition, with Anxiety Disorder appearing as the primary indexed condition, and to 1 intervention - of which Gabitril is the first listed.
NCT00236015 names 20 study sites across 9 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00236015 about?
NCT00236015 is a clinical study titled "A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder". The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).
What is the current status of trial NCT00236015?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 880 participants. The study started on 2004-11. Estimated completion is 2006-03.
What conditions does trial NCT00236015 study?
This clinical trial studies the following conditions: Anxiety Disorder.
What interventions are being tested in trial NCT00236015?
The interventions under investigation include: Gabitril (DRUG).
Who is sponsoring clinical trial NCT00236015?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00236015 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00236015's enrollment target sits among peer trials
880 4th of 20 higher than 17 of 20 other Anxiety Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
COMPLETED · Phase 3
-
Using Neurostimulation to Accelerate Change in Misophonia: a Pilot Study
RECRUITING · NA
-
Low-Intensity Focused Ultrasound and the Complex Patient
RECRUITING · NA
-
Integrated CBT to Improve Functioning in Veterans With Anxiety and Substance Use
RECRUITING · NA
-
Unified Protocol: Community Connections
RECRUITING · NA
-
Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
- NCT05525663 · 880 participants · NA
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
- NCT06580314 · 880 participants · Phase 3
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia